NeurAxis Inc. (NRXS)
NASDAQ: NRXS
· Real-Time Price · USD
2.77
0.08 (2.97%)
At close: Sep 25, 2025, 3:59 PM
2.75
-0.54%
After-hours: Sep 25, 2025, 05:05 PM EDT
2.97% (1D)
| Bid | 2.75 |
| Market Cap | 27.28M |
| Revenue (ttm) | 3.22M |
| Net Income (ttm) | -7.17M |
| EPS (ttm) | -1.05 |
| PE Ratio (ttm) | -2.63 |
| Forward PE | -7.94 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 2.78 |
| Volume | 36,996 |
| Avg. Volume (20D) | 61,298 |
| Open | 2.68 |
| Previous Close | 2.69 |
| Day's Range | 2.68 - 2.78 |
| 52-Week Range | 1.33 - 6.20 |
| Beta | 3.10 |
| Ex-Dividend Date | n/a |
About NRXS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol NRXS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for NRXS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNeurAxis Inc. is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
-19.8%
Neuraxis shares are trading lower. The company ann...
Unlock content with
Pro Subscription
4 months ago
+75.77%
Neuraxis shares are trading higher after the company announced it received FDA 510(K) clearance regarding IB-stim for the treatment of pediatric FAP associated with functional dyspepsia and FD related nausea symptoms.
